Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_assertion evidence source_evidence_literature NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_assertion SIO_000772 20080466 NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_assertion wasDerivedFrom befree-20140225 NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_assertion wasGeneratedBy ECO_0000203 NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
- befree-20140225 importedOn "2014-02-25" NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.